Kristen Willeumier, PhD
Kristen Willeumier, PhD, served as the Director of Neuroimaging Research for the Amen Clinics from 2009-2016 exploring the role of neuroimaging in clinical psychiatric practice. She has led a number of clinical research trials investigating the long-term effects of repetitive subconcussive impacts in NFL football players and on therapeutic approaches to rehabilitate brain function in athletes.
She has authored or co-authored over 50 published articles in the areas of psychiatry and neuroimaging as it applies to traumatic brain injury, posttraumatic stress disorder, autism, biomarkers of suicide, obesity, and gender differences in brain function, clinical outcomes, brain rehabilitation and applications of machine learning in psychiatric disorders. She is also the co-author of a book chapter on neuroimaging in the Wiley Blackwell Handbook of Forensic Neuroscience.
Dr. Willeumier is on the Scientific Advisory Board of Black Brain Health, LLC, founded by Dr. Keith Black, Chairman of the Department of Neurosurgery at Cedars Sinai Medical Center in Los Angeles. She also holds a position on the Scientific Advisory Board of Tate Technology, LLC™, a sports safety and technology think tank and licensing firm. Dr.Willeumier is a Senior Research Fellow with the Society for Brain Mapping and Therapeutics and sits on the Scientific Committee for the 2018 World Brain Mapping Congress with a focus on developing their Brain Health and Fitness Initiative.
Dr. Willeumier conducted her graduate research in the laboratory of Neurophysiology at the University of California, Los Angeles and the laboratory of Neurogenetics at Cedars-Sinai Medical Center using live cell imaging to investigate mechanisms of synaptic signaling in Parkinson’s disease. She received MS degrees in Physiological Science and Neurobiology and a PhD degree in Neurobiology from the University of California, Los Angeles. She was a post-doctoral fellow in the Department of Neurology at Cedars-Sinai Medical Center where she continued her work in the field of neurodegenerative disease. She was the recipient of the prestigious NIH fellowship from the National Institute of Mental Health to study the molecular mechanisms underlying Parkinson’s disease and has presented her work at national and international scientific meetings including the Society for Neuroscience and the Gordon Research Conference in Hong Kong.